DBV Technologies (NASDAQ:DBVT) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $18.77 and traded as low as $15.69. DBV Technologies shares last traded at $16.11, with a volume of 376,501 shares.

Analyst Ratings Changes

DBVT has been the topic of several recent research reports. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Citizens Jmp lifted their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, May 1st. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Finally, Guggenheim reiterated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Price Performance

The firm’s 50 day moving average is $18.77 and its 200 day moving average is $19.84. The company has a market cap of $953.87 million, a PE ratio of -3.61 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. As a group, analysts anticipate that DBV Technologies S.A. will post -0.47 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in DBVT. Artisan Partners Limited Partnership grew its position in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after buying an additional 3,257,135 shares in the last quarter. Vivo Capital LLC increased its stake in DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares during the last quarter. Siren L.L.C. purchased a new stake in shares of DBV Technologies in the 4th quarter valued at about $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.